The recurrent, albeit rare, nature of the breakpoints within BCR and JAK2 suggests a potential new diagnostic target that should be interrogated in Ph-negative CML/MPD patients. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.